Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway
Express News | Atea Pharmaceuticals Inc : Morgan Stanley Raises to Equal-Weight From Underweight
Express News | Atea Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $6.88 From $2.00
Express News | Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88
Atea Pharmaceuticals Analyst Ratings
Hold Rating on Atea Pharmaceuticals Amidst Competitive Landscape and Market Uncertainties
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Earnings Call Summary | Atea Pharmaceuticals(AVIR.US) Q2 2024 Earnings Conference
Atea Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Earnings Flash (AVIR) ATEA PHARMACEUTICALS Posts Q2 Loss $-0.48
Express News | Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Express News | Atea Pharmaceuticals Q2 Pretax Profit USD -40.279 Million
Express News | Atea Pharmaceuticals Q2 Net Income USD -40.522 Million
Express News | Atea Pharmaceuticals Q2 Operating Expenses USD 46.916 Million
Express News | Atea Pharmaceuticals Q2 Basic EPS USD -0.48
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
Atea Pharmaceuticals(AVIR.US) Director Sells US$61,144.35 in Common Stock
Atea Pharmaceuticals(AVIR.US) Officer Sells US$4,024 in Common Stock
Morgan Stanley Initiates Atea Pharmaceuticals(AVIR.US) With Sell Rating, Announces Target Price $2
No Data